CathVision
Private Company
Funding information not available
Overview
CathVision is a Copenhagen-based private company, founded in 2010, that is commercializing the ECGenius™ System, an FDA-cleared EP recording platform designed to acquire high-fidelity cardiac electrical signals. The company is augmenting this hardware with its CARDIALYTICS™ suite of AI-based analytic tools for automated, real-time analysis during procedures like atrial fibrillation ablation. By addressing the limitations of traditional, noisy EP recording systems, CathVision aims to become a new standard in the EP lab, integrating advanced signal acquisition with decision-support software.
Technology Platform
Integrated hardware-software platform combining the ECGenius™ high-fidelity electrophysiology recording system with the CARDIALYTICS™ suite of AI-based analytic tools for real-time procedural decision support.
Opportunities
Risk Factors
Competitive Landscape
CathVision competes directly with large, established medical device companies like Abbott, Boston Scientific, and Johnson & Johnson (Biosense Webster), which offer integrated EP recording and mapping systems as part of broader capital equipment and disposable catheter portfolios. Its differentiation is a singular focus on superior core signal acquisition and AI-driven analytics, rather than being one component of a larger capital stack.